Cardiff Oncology (XE7C) Price & Analysis

3 Followers

XE7C Stock Chart & Stats

€0.67

€0.04(6.67%)

At close: Jul 24 4:00 PM EDT

€0.67

€0.04(6.67%)

Day’s Range― - ―

52-Week Range€0.60 - €2.67

Previous CloseN/A

Volume0.00

Average Volume (3M)46.00

Market Cap

€72.44M

Enterprise Value€54.85M

Total Cash (Recent Filing)€34.52M

Total Debt (Recent Filing)€457.00K

Price to Earnings (P/E)―

Beta1.66

Next Earnings

Oct 29, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding77,795,250

10 Day Avg. Volume0

30 Day Avg. Volume46

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)4.14

Price to Sales (P/S)316.73

P/FCF Ratio-4.95

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€6.71

Price Target Upside902.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.5

Revenue Forecast (FY)€231.23K

Bulls Say, Bears Say

Bulls Say

Very Low LeverageExtremely low leverage limits interest burden and debt-service pressure, giving Cardiff greater flexibility than a highly indebted development-stage biotech. This supports continued investment in clinical programs and reduces solvency risk, although it does not eliminate the need for equity funding.

License Clarity And CollaborationResolving the license dispute removes a material source of legal uncertainty around Cardiff’s lead asset and preserves collaboration with Nerviano. Clearer exclusivity, economics, governance, and development obligations can support more disciplined execution as onvansertib advances toward Phase 3.

Near-term Funding For Pipeline DevelopmentThe financing provides additional capital to sustain operations and advance Cardiff’s oncology pipeline over the near term. Institutional and insider participation may support execution, while the proceeds can reduce immediate funding pressure as the company pursues clinical and regulatory milestones.

Bears Say

Pre-commercial Revenue ProfileCardiff has not established a meaningful recurring commercial revenue base, leaving the business dependent on clinical progress rather than product sales. Minimal and declining revenue limits internal funding capacity and makes future financial performance highly contingent on successful development of onvansertib.

Large Ongoing Losses And Cash BurnLosses are substantial relative to revenue and translate into direct cash outflows, showing that Cardiff’s research-intensive model currently consumes capital faster than it generates it. Persistent negative cash flow increases the importance of future financing, clinical efficiency, and successful commercialization.

Equity Erosion And Dilution DependenceThe sharp reduction in equity reflects cumulative losses and cash consumption, while the financing structure expands potential future share count through warrants. Continued reliance on equity funding can dilute existing holders and may constrain strategic flexibility if additional capital is required.

Cardiff Oncology News

Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Cardiff Oncology (CRDF) to Buy from Neutral with a $9 price target The company reached...

29d ago

CRDF

Cardiff Oncology, Nerviano Medical Sciences reach settlement

Cardiff Oncology (CRDF) and Nerviano Medical Sciences announced that they have reached a settlement and amended their 2017...

30d ago

CRDF

Cardiff Oncology Amends Onvansertib License, Resolves Litigation

Cardiff Oncology ( ($CRDF) ) has shared an announcement. On September 14, 2026, Cardiff Oncology and Nerviano Medical...

30d ago

CRDF

Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

Reports Q2 revenue $104,000, consensus $62,780. “The second quarter was an important period of progress for Cardiff, highlighted...

2M ago

CRDF

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Cardiff Oncology (CRDF) to Market Perform from Outperform. Post-Q2 results, the firm said the company’s...

2M ago

CRDF

Okta upgraded, Gap downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

BSP

GAP

Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QMCO) ), ( ($ONON) ), ( ($CRDF)...

2M ago

ADSK

CRDF

CRDF Earnings this Week: How Will it Perform?

Cardiff Oncology, Inc. (CRDF) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

3M ago

CRDF

Cardiff Oncology completes $10 million financing transaction

Cardiff Oncology ( ($CRDF) ) just unveiled an announcement. On July 14, 2026, Cardiff Oncology entered into agreements...

3M ago

CRDF

Cardiff Oncology announces $10M registered direct offering

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Published first on TheFly...

3M ago

CRDF

Cardiff, Verastem, Fluence, Quantum-Si, Opera Insider Shock

Insiders have been trading these 5 stocks: (($CRDF)), (($VSTM)), (($FLNC)), (($QSI)) and (($OPRA)). Here is a breakdown of...

4M ago

QSI

CRDF

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Amplitech Group Inc (AMPG)...

4M ago

SLS

AMPG

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Ares Capital (ARCC) 30.09%...

4M ago

YSS

ARCC

Cardiff Oncology Shareholders Approve Directors and Equity Plan

Cardiff Oncology ( ($CRDF) ) just unveiled an update. On June 11, 2026, Cardiff Oncology, Inc. held its...

4M ago

CRDF

XE7C FAQ

What was Cardiff Oncology, Inc.’s price range in the past 12 months?

Cardiff Oncology, Inc. lowest stock price was €0.60 and its highest was €2.67 in the past 12 months.

What is Cardiff Oncology, Inc.’s market cap?

Cardiff Oncology, Inc.’s market cap is €72.44M.

When is Cardiff Oncology, Inc.’s upcoming earnings report date?

Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 29, 2026 which is in 15 days.

How were Cardiff Oncology, Inc.’s earnings last quarter?

Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -€0.125 earnings per share for the quarter, missing the consensus estimate of -€0.107 by -€0.018.

Is Cardiff Oncology, Inc. overvalued?

According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiff Oncology, Inc. pay dividends?

Cardiff Oncology, Inc. does not currently pay dividends.

What is Cardiff Oncology, Inc.’s EPS estimate?

Cardiff Oncology, Inc.’s EPS estimate is -0.12.

How many shares outstanding does Cardiff Oncology, Inc. have?

Cardiff Oncology, Inc. has 77,795,250 shares outstanding.

What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?

Cardiff Oncology, Inc. reported an EPS of -€0.125 in its last earnings report, missing expectations of -€0.107. Following the earnings report the stock price went down -1.724%.

Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?

Currently, no hedge funds are holding shares in DE:XE7C

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cardiff Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-103.08%

Trailing 12-Months

Asset Growth

-50.71%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Cardiff Oncology (XE7C) Earnings & Revenues

Historic Earnings Reports

XE7C Stock 12 Month Forecast

Average Price Target

€6.71

▲(902.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","9":"€9","-1":"-€1","1.5":"€1.5","6.5":"€6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.05771476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€8.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.7147623,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€6.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.37180984,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.5715165199999999,2.11203304,2.6525495599999998,3.1930660799999995,3.733582599999999,4.27409912,4.8146156399999995,5.355132159999999,5.895648679999999,6.436165199999999,6.976681719999999,7.517198239999999,{"y":8.05771476,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.4682124846153846,1.9054249692307692,2.342637453846154,2.7798499384615383,3.217062423076923,3.654274907692308,4.091487392307692,4.528699876923077,4.965912361538462,5.403124846153847,5.840337330769231,6.277549815384615,{"y":6.7147623,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.031,1.3649084492307693,1.6988168984615384,2.032725347692308,2.366633796923077,2.700542246153846,3.0344506953846153,3.3683591446153844,3.7022675938461536,4.036176043076923,4.370084492307692,4.703992941538462,5.037901390769231,{"y":5.37180984,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.664,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.862,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.425,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.362,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.552,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.322,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.301,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.312,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.056,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.662,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.776,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.031,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >